Oncolytics Biotech Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 26, 2006, serves as a report of a foreign private issuer for Oncolytics Biotech Inc., a Canadian biotechnology company headquartered in Calgary, Alberta. The filing primarily contains certifications of interim filings for the period ending March 31, 2006, pursuant to Multilateral Instrument 52-109.
Financial Metrics
The provided text contains only certification statements and does not include specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not provide specific details regarding material changes in financial position or operations compared to prior periods. It confirms only that the interim filings fairly present the financial condition and results of operations.
Guidance, Outlook, and Risks
There is no management commentary, forward-looking guidance, or specific discussion of risks and contingencies in this text. The document focuses on the certification by the Chief Executive Officer and Chief Financial Officer that disclosure controls and procedures are in place and that the interim filings do not contain material misstatements.
Key Facts for Investor Verification
- The filing is a certification of interim financial statements for the quarter ended March 31, 2006, rather than the financial statements themselves.
- Specific financial performance metrics (revenue, net income, cash position) are not disclosed in this text and must be verified in the referenced interim filings.
- The company is a foreign private issuer filing under Form 20-F.
- Signatories include Bradley G. Thompson (President and CEO) and Doug Ball (CFO), who certified the accuracy of the interim disclosures.